NeoStem, Inc. (NASDAQ: NBS) is focused on the emerging cellular therapy industry. The company’s business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides NeoStem with capabilities for cost effective in-house product development and immediate revenue and cash flow generation. For more information, visit the company’s website at www.neostem.com